FTC Prevails in Reverse Payment Case

Publication Date16 April 2021
SubjectFTC,Reverse Payment Settlement Agreements,Patents,SCOTUS,Hatch-Waxman,Generic Drugs,Patent Litigation,Pharmaceutical Patents,Rule-of-Reason Analysis,FTC v Actavis,Exclusivity,Pharmaceutical Industry,Abbreviated New Drug Application (ANDA)
AuthorKevin Noonan
Law FirmMcDonnell Boehnen Hulbert & Berghoff LLP

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT